Alzchem Group AG
ACT
ISIN DE000A2YNT30 / Valor 48678352
Alzchem Group AG
UMushroom community rating:
About company
Alzchem Group AG is a diversified chemical manufacturer with a strong presence in the Southeast Bavarian chemical triangle and an additional production site in Sundsvall, Sweden. The company extends its global reach through sales companies located in Atlanta (USA), Shanghai (China), and Coventry (England). Alzchem is engaged in the development and production of specialty chemicals and advanced materials, catering to a wide range of industries. Its product portfolio includes high-quality guanidine salts, which are critical in the extraction of DNA and RNA for molecular diagnostics, including Covid-19 PCR test kits. The company also plays a significant role in the thermoset industry, participating in forums such as the TRFA Annual Meeting to exchange knowledge on epoxy and other thermoset materials. Furthermore, Alzchem targets the nutrition sector by marketing premium products for food and sports nutrition, dietary supplements, and cosmetics production. With a focus on innovation and quality, Alzchem positions itself as a key player in supporting developments in hydrogen-powered vehicles, lightweight construction, wind energy, and molecular diagnostics.
Summarized from source with an LLMView SourceSector: IndustrialsLatest Results (08.11.2025):
Alzchem Group AG's Q3 2025 results demonstrate a robust financial performance with steady group sales and a disproportionately strong rise in earnings. In Q3 2025, the Group recorded sales of approximately EUR 137.3 million, contributing to a nine‐month total of EUR 424.8 million, while EBITDA increased by 12% year-on-year to reach EUR 86.2 million with the EBITDA margin improving from 18.5% to 20.3%. These positive outcomes were achieved despite challenges such as increased energy prices and adverse currency effects, and they underline the effectiveness of the company's strategic focus on specialty chemicals and productive capacity utilization.
Sales Performance
In Q3 2025, Alzchem Group AG delivered a 6% increase in quarterly sales compared to Q3 2024, with nine-month group sales rising to EUR 424.8 million from EUR 415.2 million, underscoring the strength of the diversified product portfolio and the increasing demand in niche specialty chemical markets.
EBITDA and Margin Growth
The company's EBITDA for Q3 2025 grew significantly by 12% to EUR 86.2 million, with the EBITDA margin rising from 18.5% to 20.3%. This disproportionate jump in earnings highlights operational improvements and enhanced capacity utilization, particularly in the specialty chemicals segment.
Cash Flow and Investment
Alzchem Group AG reported a strongly positive free cash flow of EUR 48.1 million despite a considerable increase in capital expenditure. This robust cash generation complements ongoing expansion investments, including the successful commissioning of additional creatine capacities and the timely construction of a new nitroguanidine production plant.
Strategic Developments
During Q3 2025, the company advanced several strategic initiatives such as launching a creatine cooperation with Ehrmann (Creavitalis® now available in stores), expanding production capacities for new chemicals, and maintaining its market position amid competitive pressure. The continued investment in innovation and capacity, along with confirmed forecasts for another record year in 2025, positions Alzchem Group AG strongly for future growth.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
1573 M
Market cap (USD)
11,099
Daily traded volume (Shares)
59 / 55.4
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Hongkun Zhu
EQUITIES OF THE SAME SECTOR
